FOXO3 and idiopathic pulmonary fibrosis: Since we are interested in identifying novel therapeutic approaches to prevent or limit the progression of IPF, re-activation of FoxO3a or inhibition of the FoxO3a inactivation may provide an approach not only for slowing IPF disease progression but also for longevity.